Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma

被引：12

作者：

Trudel, Suzanne ^{[1
]}

McCurdy, Arleigh ^{[2
]}

Fu, Molei ^{[3
]}

Sutherland, Heather J. ^{[4
]}

Louzada, Martha L. ^{[5
]}

Chu, Michael P. ^{[6
]}

White, Darrell J. ^{[7
,8
]}

Mian, Hira S. ^{[9
]}

Kotb, Rami ^{[10
]}

Othman, Ibraheem ^{[11
]}

Kardjadj, Moustafa ^{[12
]}

Gul, Engin ^{[13
]}

Reece, Donna E. ^{[3
]}

机构：

[1] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada

[2] Ottawa Hosp, Dept Med, Div Hematol, Ottawa, ON, Canada

[3] Canadian Myeloma Res Grp CMRG, Vaughan, ON, Canada

[4] Vancouver Gen Hosp, Div Hematol, Vancouver, BC, Canada

[5] Univ Western Ontario, London Hlth Sci Ctr, London, ON, Canada

[6] Cross Canc Inst, Dept Oncol, Edmonton, AB, Canada

[7] Dalhousie Univ, Halifax, NS, Canada

[8] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada

[9] McMaster Univ, Dept Oncol, Hamilton, ON, Canada

[10] CancerCare Manitoba, Dept Med Oncol & Hematol, Winnipeg, MB, Canada

[11] Saskatchewan Canc Agcy, Allan Blair Canc Ctr, Regina, SK, Canada

[12] Canadian Myeloma Res Grp, Toronto, ON, Canada

[13] Canadian Myeloma Res Grp CMRG, Concord, ON, Canada

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-160445

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：7306 / 7307

页数：2

共 50 条

[41] Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
Suvannasankha, Attaya
Bahlis, Nizar
Trudel, Suzanne
Weisel, Katja
Koenecke, Christian
Oriol, Albert
Voorhees, Peter M.
Alonso, Aranzazu A.
Callander, Natalie S.
Mateos, Maria-Victoria
Reddy, Nishitha
Hakim, Shawn
Lamacchia, John
Patel, Nashita
Williams, Danae
Jewell, Roxanne. C.
Zhou, Xiangdong
Gupta, Ira
Opalinska, Joanna
Nooka, Ajay K.
CANCER, 2024, 130 (15) : 2629 - 2641
[42] Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy
Fazio, Francesca
Petrucci, Maria Teresa
Corvatta, Laura
Piciocchi, Alfonso
Pepa, Roberta Della
Tacchetti, Paola
Musso, Maurizio
Zambello, Renato
Belotti, Angelo
Bringhen, Sara
Antonioli, Elisabetta
Conticello, Concetta
Renzo, Nicola Di
De Stefano, Valerio
Musto, Pellegrino
Gamberi, Barbara
Derudas, Daniele
Boccadoro, Mario
Offidani, Massimo
More, Sonia
EJHAEM, 2024, 5 (03): : 485 - 493
[43] FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma
Baines, Andrea C.
Ershler, Rachel
Kanapuru, Bindu
Xu, Qing
Shen, Guoxiang
Li, Liang
Ma, Lian
Okusanya, Olanrewaju O.
Simpson, Natalie E.
Nguyen, Wanda
Theoret, Marc R.
Pazdur, Richard
Gormley, Nicole J.
CLINICAL CANCER RESEARCH, 2022, 28 (21) : 4629 - 4633
[44] Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
Dharshan Sivaraj
Michael M Green
Yubin Kang
Gwynn D Long
David A Rizzieri
Zhiguo Li
Anderson H Garrett
Jackie L McIntyre
Nelson J Chao
Cristina Gasparetto
Blood Cancer Journal, 8
[45] Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
Sivaraj, Dharshan
Green, Michael M.
Kang, Yubin
Long, Gwynn D.
Rizzieri, David A.
Li, Zhiguo
Garrett, Anderson H.
McIntyre, Jackie L.
Chao, Nelson J.
Gasparetto, Cristina
BLOOD CANCER JOURNAL, 2018, 8
[46] Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
Nooka, Ajay K.
Weisel, Katja
van de Donk, Niels W. C. J.
Routledge, David
Otero, Paula Rodriguez
Song, Kevin
Quach, Hang
Callander, Natalie
Minnema, Monique C.
Trudel, Suzanne
Jackson, Nicola A.
Ahlers, Christoph M.
Im, Ellie
Cheng, Shinta
Smith, L.
Hareth, Nahi
Ferron-Brady, Geraldine
Brouch, Maria
de Oca, Rocio Montes
Paul, Sofia
Holkova, Beata
Gupta, Ira
Kremer, Brandon E.
Richardson, Paul
FUTURE ONCOLOGY, 2021, 17 (16) : 1987 - 2003
[47] DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)
Popat, Rakesh
Nooka, Ajay
Stockerl-Goldstein, Keith
Abonour, Rafat
Ramaekers, Ryan
Khot, Amit
Forbes, Adam
Lee, Cindy
Augustson, Bradley
Spencer, Andrew
Mateos, Maria-Victoria
Chopra, Bikramjit
Rogers, Rachel
Smith, Deborah A.
Davidge, Jacqueline
de Oca, Rocio Montes
Ferron-Brady, Geraldine
Yeakey, Anne
Talekar, Mala
Kremer, Brandon E.
Gupta, Ira
Quach, Hang
BLOOD, 2020, 136
[48] Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial
Kumar, Sudhir
Sharma, Atul
Malik, Prabhat Singh
Gogia, Ajay
Pathak, Neha
Sahoo, Ranjit Kumar
Gupta, Ritu
Prasad, Chandra Prakash
Kumar, Lalit
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (02) : 288 - 297
[49] A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Gasparetto, Cristina
Bowles, Kristian M.
Abdallah, Al-Ola
Morris, Lura
Mander, Gudrun
Coppola, Sheryl
Wang, Jing
Ross, Jeremy A.
Bueno, Orlando F.
Arriola, Emma
Mateos, Maria Victoria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11): : 775 - 784
[50] Belantamab mafodotin in patients with relapsed/refractory multiple myeloma who are triple-refractory: a retro-prospective Italian observational study
Offidani, Massimo
More, Sonia
Cavo, Michele
Derudas, Daniele
Di Raimondo, Francesco
Cuneo, Antonio
Baldini, Luca
Della Pepa, Roberta
Musso, Maurizio
Boccadoro, Mario
Musto, Pellegrino
Belotti, Angelo
Fioritoni, Francesca
Di Renzo, Nicola
Mele, Anna
Gamberi, Barbara
De Paoli, Lorenzo
Zambello, Renato
Grammatico, Sara
Brociner, Marco
Fazio, Francesca
Petrucci, Maria-Teresa
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S205 - S205

← 1 2 3 4 5 →